Trial Profile
An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) Administered in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Raxibacumab (Primary)
- Indications Anthrax
- Focus Pharmacodynamics
- Sponsors Human Genome Sciences
- 11 May 2021 Results of a pooled population pharmacokinetics analysis of data from 3 clinical trials (HGS1021-C1063,HGS1021-C1064 and HGS1021-C1069) published in the British Journal of Clinical Pharmacology
- 30 Dec 2013 Planned number of patients changed from 20 to NULL.
- 30 Dec 2013 New trial record